Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)

Mohsen Sadatsafavi, Ruth B Murray, Nasloon Ali, Trung N Tran, David Price, ISAR FIRE Working Group

Research output: Contribution to journalAbstractpeer-review

5 Downloads (Pure)

Abstract

Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.
Original languageEnglish
Article numberA1614
Number of pages1
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume203
Early online date19 May 2021
DOIs
Publication statusPublished - 2021
EventATS International Conference Committee: ATS 2021 - Virtual event
Duration: 14 May 202119 May 2021
https://conference.thoracic.org/

Fingerprint

Dive into the research topics of 'Worldwide Characterization of Severe Asthma Patients Eligible for both anti–IL-5 and anti-IgE Biologic Therapy: data from the International Severe Asthma Registry (ISAR)'. Together they form a unique fingerprint.

Cite this